Opyl Ltd. (AU:PKY)
ASX:PKY
Want to see AU:PKY full AI Analyst Report?
PKY Stock Chart & Stats
AU$0.03
--
Market closed
AU$0.03
--
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.07
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.13M
Market Cap
AU$32.78M
Enterprise ValueAU$14.22M
Total Cash (Recent Filing)AU$580.84K
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.91
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding607,077,760
10 Day Avg. Volume406,454
30 Day Avg. Volume1,132,050
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-21.63
Price to Sales (P/S)208.90
P/FCF Ratio-4.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AI-driven Drug Discovery FocusOpyl’s core AI and data-driven focus addresses a structural need in drug discovery to reduce time and cost to clinic. A software-first computational offering can scale across programs and partners, enabling recurring service contracts and durable client relationships if execution continues.
Sector Tailwinds (biotech Enablement)The company sits in healthcare information services and biotech enablement, a segment with secular demand as pharma increasingly outsources computational discovery. Structural adoption of data science in R&D supports medium-term demand for Opyl’s capabilities independent of short-term market moves.
Very Lean Operating StructureAn extremely small headcount implies a very lean fixed-cost base, allowing the business to operate capital-efficiently. For an AI/software-first model this can extend runway, reduce break-even needs and enable scalable outsourcing or partnerships until revenues recover.
Bears Say
Severe Revenue ContractionAn ~86% year-over-year revenue decline reflects a severe loss of commercial traction and weak product-market fit. Such a collapse erodes scale economics, damages customer momentum, and materially lengthens the timeline to rebuild recurring revenues and reach sustainable margins.
Negative Shareholders' EquityNegative equity signals accumulated losses that have depleted book capital, limiting borrowing capacity and increasing funding risk. This structural balance-sheet weakness constrains investment, heightens dilution risk on future raises, and reduces strategic optionality over the medium term.
Persistent Cash Burn & Worsening FCFConsistent negative operating and free cash flow, with a ~39% deterioration in FCF, means the business is not self-funding. Persistent cash burn forces reliance on external financing, limiting flexibility and increasing solvency and dilution risks if revenue recovery does not materialize.
Opyl Ltd. News
PKY FAQ
What was Opyl Ltd.’s price range in the past 12 months?
Opyl Ltd. lowest share price was AU$0.01 and its highest was AU$0.07 in the past 12 months.
What is Opyl Ltd.’s market cap?
Opyl Ltd.’s market cap is AU$32.78M.
When is Opyl Ltd.’s upcoming earnings report date?
Opyl Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 72 days.
How were Opyl Ltd.’s earnings last quarter?
Opyl Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
Is Opyl Ltd. overvalued?
According to Wall Street analysts Opyl Ltd.’s price is currently Overvalued.
Does Opyl Ltd. pay dividends?
Opyl Ltd. does not currently pay dividends.
What is Opyl Ltd.’s EPS estimate?
Opyl Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Opyl Ltd. have?
Opyl Ltd. has 607,077,760 shares outstanding.
What happened to Opyl Ltd.’s price movement after its last earnings report?
Opyl Ltd. reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.448%.
Which hedge fund is a major shareholder of Opyl Ltd.?
Currently, no hedge funds are holding shares in AU:PKY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Opyl Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.74%
12-Months-Change
Fundamentals
Return on Equity
-1122.02%
Trailing 12-Months
Asset Growth
129.09%
Trailing 12-Months
Company Description
Opyl Ltd.
Pathkey.AI Ltd is an Australian digital health firm that harnesses artificial intelligence (AI) to advance clinical trials and improve the predictability of patient outcomes, particularly within Australia. The company presents a suite of AI-driven solutions: TrialKey, a sophisticated platform for simulating and optimizing trial designs to boost success rates, and TrialGen, an AI-powered utility crafted to simplify the clinical trial design process. They extend their services to a diverse clientele, encompassing biopharmaceutical companies, MedTech innovators, governmental agencies, and various healthcare organizations. Established in Sydney in 1994, the entity known today as Pathkey.AI Ltd will formally change its name from Opyl Limited in August 2025.
Technical Analysis
Global Health Limited
―
―
Singular Health Group Ltd
―
HitIQ Limited
―
InteliCare Holdings Limited
―
Options Prices
Currently, No data available
---